Journal of B.U.ON. : official journal of the Balkan Union of Oncology · 2013
miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Firatligil B, Biray Avci C, Baran Y
Аннотация
PURPOSE: In this study we examined the expression levels of miR-17 which possesses oncogenic activities through downregulation of CDKN1A, p21 and E2F1 tumor suppressor genes, in imatinib sensitive and resistant chronic myeloid leukemia (CML) cells. On the other hand, we also determined the expression levels of miR-17 in response to tyrosine kinase inhibitors imatinib, nilotinib and dasatinib used for the treatment of CML.
METHODS: The expression profiles of miR-17 were analysed by Stem-Loop reverse transcription (RT) polymerase chain reaction (PCR).
RESULTS: The results revealed significant increase in the expression levels of miR-17 in imatinib sensitive and resistant cells compared to peripheral blood mononuclear cells (PBMCs). On the other hand, significant decrease was observed in miR-17 levels in response to imatinib, nilotinib and dasatinib.
CONCLUSION: These results may imply that miR-17 can be used for diagnosis and treatment of CML.
METHODS: The expression profiles of miR-17 were analysed by Stem-Loop reverse transcription (RT) polymerase chain reaction (PCR).
RESULTS: The results revealed significant increase in the expression levels of miR-17 in imatinib sensitive and resistant cells compared to peripheral blood mononuclear cells (PBMCs). On the other hand, significant decrease was observed in miR-17 levels in response to imatinib, nilotinib and dasatinib.
CONCLUSION: These results may imply that miR-17 can be used for diagnosis and treatment of CML.
Предметные рубрики MeSH
Antineoplastic AgentsBenzamidesDasatinibDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansImatinib MesylateK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMicroRNAsMolecular Targeted TherapyPiperazinesProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidinesReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionThiazoles